Company news
Okyo Pharma Limited (NASDAQ:OKYO) news
Okyo Pharma Limited news releases on 6ix. Latest, Oct 6, 2026: OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod…
Press releases & updates
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
October 5, 2026
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
October 5, 2026
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
October 6, 2026
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
September 28, 2026
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
September 28, 2026
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026
September 9, 2026
OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference
September 8, 2026
OKYO Pharma : Amendment to Annual Report by Foreign Issuer (Form 20-F/A)
August 7, 2026
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
July 28, 2026
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
July 27, 2026
OKYO Pharma Announces Purchase of Shares by Director
July 23, 2026
OKYO Pharma Announces Purchase of Shares by Chief Executive Officer
July 23, 2026
OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director
July 22, 2026
OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
July 22, 2026
OKYO Pharma Announces Purchase of Shares by Chairman
July 21, 2026
OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans
July 20, 2026
OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain
July 7, 2026
OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium
July 7, 2026
OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD
May 18, 2026
OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May
April 29, 2026
OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting
April 7, 2026
OKYO Pharma Announces Chairman and Founder Acquires Shares
March 19, 2026
OKYO Pharma Announces Director Acquires Shares
March 19, 2026
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares
March 19, 2026
OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain
March 18, 2026
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress
February 23, 2026
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
February 12, 2026
OKYO Pharma Announces Public Offering of Ordinary Shares
February 12, 2026
OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners
February 11, 2026
OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer
February 10, 2026
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
January 30, 2026
OKYO Pharma Announces Successful Type C Meeting with the FDA
January 28, 2026
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
January 23, 2026
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer
January 5, 2026
OKYO Pharma to Ring the Opening Bell at Nasdaq
December 19, 2025
OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain
December 11, 2025
OKYO Pharma to Present at OIS XV in San Diego
November 18, 2025
OKYO Pharma to Present at BIO-Europe 2025 in Vienna
October 29, 2025
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
September 22, 2025
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
July 17, 2025
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
July 16, 2025
OKYO Pharma to Present at the Bio International Convention
June 11, 2025
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
May 19, 2025